Clinical Trials Logo

Acetaldehyde Toxicity clinical trials

View clinical trials related to Acetaldehyde Toxicity.

Filter by:
  • None
  • Page 1

NCT ID: NCT00661141 Completed - ALDH2 Deficiency Clinical Trials

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Start date: April 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This trial will evaluate if fomepizole (4-methylpyrazole)can treat symptoms associated with alcohol intolerance due to aldehyde dehydrogenase 2 (ALDH2) Deficiency, an inherited metabolic disorder. These symptoms include flushing, nausea, headache, shortness of breath and dizziness, resulting from exposure to acetaldehyde, the primary metabolite of ethanol. Long-term, serious health risks have been associated with repeated exposure to acetaldehyde, a carcinogen, among ALDH2-deficient individuals.